In vitro method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject
A non-invasive in vitro method using xylose derived from Gaxilose hydrolysis quantitatively assesses intestinal barrier integrity and permeability, addressing the limitations of current methods by providing precise disease monitoring and treatment evaluation.
Patent Information
- Application Number
- PCT/EP2026/063617
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for assessing intestinal barrier integrity and permeability are invasive, unreliable, and lack a nuanced, quantitative approach, which is crucial for early detection and monitoring of gastrointestinal and systemic diseases.
A non-invasive in vitro method measuring the amount or concentration of a five-carbon monosaccharide, preferably xylose, derived from the hydrolysis of a beta-galactoside substrate like Gaxilose, to assess intestinal lactase enzyme activity, providing a quantitative and graded evaluation of intestinal barrier function.
The method offers a reliable, direct, and specific indication of intestinal barrier integrity and permeability, enabling precise monitoring of disease progression and treatment response, with correlations to established markers like zonulin, and allowing for the detection of subtle changes and clinical improvements.
Smart Images

Figure IMGF000017_0001_TABLE 
Figure IMGF000019_0001_TABLE 
Figure IMGF000021_0001_TABLE
Abstract
Description
[0001] IN VITRO METHOD FOR ASSESSING AND / OR MONITORING THE DEGREE OF INTESTINAL BARRIER INTEGRITY AND / OR PERMEABILITY IN A SUBJECT FIELD OF THE INVENTION
[0002] The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject.
[0003] STATE OF THE ART
[0004] Gaxilose is a synthetic compound used to assess the activity of the enzyme lactase (which digests lactose) in the small intestine. If intestinal lactase is present and active, it breaks down Gaxilose releasing xylose, which enters the bloodstream and then it is excreted in the urine. By measuring the amount of xylose in the urine or the concentration in serum, the level of lactase activity in the small intestine can be correlated.
[0005] Xylose is a monosaccharide, a type of sugar commonly found in plant materials, such as wood and straw. It is a pentose sugar with the chemical formula CsHwOs and plays an important role in human metabolism.
[0006] The lactase-florizine hydrolase (LPH) complex is a key enzyme in the digestion of lactose, the sugar found in milk, in humans and other mammals, and is known as lactase. Lactase is an enzyme located in the small intestine that breaks down lactose (a disaccharide found in milk) into its constituent monosaccharides: glucose and galactose. In individuals with sufficient lactase activity, lactose is efficiently digested and the monosaccharides absorbed. However, in individuals with lactase deficiency or insufficiency, lactose remains undigested and can lead to symptoms of lactose intolerance consequence of the digestion of lactose by the bacteria in the large intestine.
[0007] The intestinal barrier is a dynamic and complex structure that regulates the passage of substances from the lumen of the intestine into the bloodstream. It is constituted by the intestinal epithelial cells, the tight junctions between them, the mucus layer, intestinal microbiota and immune cells within the gut-associated lymphoid tissue (GALT). Intestinal barrier integrity refers to the proper functioning of this barrier, ensuring selective permeability to nutrients while preventing the entry of harmful pathogens, toxins, and undigested food particles. A compromised intestinal barrier is associated with several gastrointestinal andsystemic diseases, including inflammatory bowel disease (IBD), celiac disease, and other autoimmune conditions.
[0008] Intestinal permeability refers to the ability of the intestinal barrier to control the passage of substances. In a healthy state, the intestinal barrier is selectively permeable, allowing the absorption of nutrients and water, while blocking the passage of harmful agents. Increased intestinal permeability, often referred to as “leaky gut,” occurs when the barrier becomes damaged or weakened, leading to the unintended passage of bacteria, toxins, and other harmful molecules into the bloodstream. This condition can trigger systemic inflammation and has been implicated in the pathogenesis of several diseases, including autoimmune disorders, allergies, and metabolic diseases.
[0009] A growing body of evidence has shown that alterations in intestinal barrier integrity and permeability are linked to a variety of diseases. These include:
[0010] • Celiac Disease: A chronic autoimmune disorder triggered by the ingestion of gluten, leading to damage to the small intestine's epithelial lining and increased permeability.
[0011] • Inflammatory Bowel Disease (IBD): A group of inflammatory conditions, including Crohn's disease and ulcerative colitis, that result in damage to the intestinal barrier and loss of permeability control.
[0012] • Irritable Bowel Syndrome (IBS): A functional gastrointestinal disorder that is often associated with abnormal intestinal permeability, leading to symptoms such as bloating, diarrhea, and constipation.
[0013] • Type 1 Diabetes: Autoimmune destruction of insulin-producing cells may be linked to increased intestinal permeability and microbial translocation.
[0014] • Metabolic Disorders: Conditions such as obesity and type 2 diabetes are also associated with alterations in gut permeability, which may contribute to inflammation and insulin resistance.
[0015] • Food Allergies: Increased intestinal permeability can lead to the inappropriate absorption of allergens, triggering immune responses and allergic reactions.
[0016] In addition to these, altered intestinal permeability has been implicated in neurological conditions such as autism spectrum disorders and Alzheimer's disease, where gut-brain interactions are believed to play a role.Assessing intestinal barrier integrity and intestinal permeability is critical for understanding the pathophysiology of several gastrointestinal and systemic diseases. A non-invasive, reliable method to evaluate these parameters can aid in the early detection and monitoring of diseases linked to barrier dysfunction. This is particularly important in conditions like IBD, Crohn disease, celiac disease, viral infections, and food allergies, where impaired barrier function precedes or contributes to disease onset and progression.
[0017] Additionally, monitoring of the integrity and intestinal permeability provides valuable insight into treatment efficacy in conditions where the intestinal barrier is compromised. For instance, therapies aimed at improving gut barrier function could benefit from the present invention to assess the success of intervention strategies.
[0018] Particularly, the ability to measure the degree of integrity and / or permeability can offer a quantitative approach to assess disease severity, predict disease course, and personalize treatment regimens.
[0019] The present invention is thus focused on solving this technical problem and an innovative method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject is herein provided.
[0020] DESCRIPTION OF THE INVENTION
[0021] Brief description of the invention
[0022] The present invention refers to a non-invasive in vitro method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject. Particularly, the present invention provides an innovative approach for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject by measuring the amount or concentration of a five-carbon monosaccharide (preferably xylose) derived from the hydrolysis of a beta-galactoside substrate (preferably Gaxilose) in a biological sample obtained from the subject. This method is particularly useful for monitoring diseases and conditions associated with intestinal barrier dysfunction, such as IBD, celiac disease, IBS, food allergies or autoimmune disorders.
[0023] It is highly important to note that the present invention specifically assess the degree of intestinal barrier integrity and / or permeability, offering a quantitative and graded approach. This aspect of the invention is highly important because it moves beyond a binary or qualitative assessment of intestinal barrier function. By specifically targeting the degree of intestinalbarrier integrity and / or permeability, the invention enables a quantitative and graded evaluation. This allows for more precise monitoring of disease progression, early detection of subtle changes, and better assessment of treatment response. Such a nuanced approach is especially valuable in clinical and research settings where small variations in barrier function can have significant biological or therapeutic implications.
[0024] More specifically, the invention provides a method that includes administering an effective amount of a beta-galactoside substrate (preferably Gaxilose). The beta-galactoside substrate (preferably Gaxilose) is broken down into five-carbon monosaccharides (preferably xylose) in the presence of intestinal beta-galactosidase (preferably lactase). The amount or concentration of the five-carbon monosaccharide (preferably xylose) in biological samples represents a direct relationship with the activity of the intestinal beta-galactosidase (preferably lactase) enzyme which serves for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject. So, the invention encompasses classifying degrees of permeability and identifying intestinal barrier dysfunction in clinical and research settings.
[0025] As shown in Examples 2.1 to 2.8 below, lactase enzyme activity is assessed (departing from xylose) and zonulin levels as an indicator of the degree of intestinal barrier integrity and / or permeability. Notably, the results obtained from measuring xylose concentration or amount in biological samples show a strong correlation with zonulin levels, a well-established marker of tight junction integrity and intestinal permeability. The consistency between the results obtained from both molecules provides robust evidence supporting the validity and reliability of using lactase enzyme activity, through xylose measurement, as a surrogate molecule for quantitatively assessing intestinal barrier function.
[0026] This correlation between xylose and zonulin demonstrates that the method described herein is not only effective in detecting alterations in intestinal permeability but also validates the use of the present invention as a practical, non-invasive method for assessing the degree of intestinal barrier integrity and / or permeability in clinical and diagnostic settings.
[0027] However, this correlation serves primarily to validate the use of xylose, not to suggest redundancy between the two molecules. Importantly, xylose offers several advantages over zonulin. Zonulin is an indirect measure of intestinal permeability and is typically assessed in stool samples. Its levels can be influenced by environmental and behavioral factors, such as diet, smoking, and microbiota composition, potentially leading to variability and reduced specificity. In contrast, xylose is preferably measured in urine and directly reflects intestinallactase enzyme activity, offering a more specific and reliable indication of functional barrier integrity. Furthermore, the amount of xylose detected after administration of Gaxilose depends solely on the presence and activity of endogenous intestinal lactase, making it a direct and quantifiable molecule. The use of zonulin in this context is not intended as an alternative or replacement, but rather as a supporting measure to confirm the validity of the xylose-based assessment.
[0028] On the other hand, Example 2.7 below demonstrates that, when damage occurs in the intestinal barrier, Gaxilose does not pass through intestinal barrier. Kindly note that if Gaxilose were absorbed by intestinal barrier, it would bypass hydrolysis by intestinal lactase, and the excreted xylose would no longer be a reliable molecule, as it would not correlate with lactase activity.
[0029] Example 2.7 demonstrates that Gaxilose does not pass through the damaged intestinal barrier, and therefore it remains available to be cleaved by lactase present in the intestinal enterocytes. Finally, while the present invention exemplifies the use of Gaxilose as a P-galactoside substrate, xylose as the detectable five-carbon monosaccharide, and endogenous intestinal lactase as the P-galactosidase enzyme, it is understood that the invention is not limited thereto. Equivalent combinations involving other P-galactoside substrates, five-carbon monosaccharides, and P-galactosidase enzymes may be used, provided that the enzymatic cleavage results in a detectable monosaccharide that can serve to assess intestinal enzyme activity and / or barrier integrity.
[0030] So, the first embodiment of the present invention refers to an in vitro method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject, the method comprising: a) administering an effective amount of a beta-galactoside substrate to the subject; and b) measuring the amount or concentration of a five-carbon monosaccharide derived from the hydrolysis of the beta-galactoside substrate in a biological sample obtained from the subject; wherein the amount or concentration of the five-carbon monosaccharide directly correlates with the level of beta-galactosidase enzyme activity in the intestine of the subject, and wherein the level of beta-galactosidase enzyme activity is indicative of the degree of intestinal barrier integrity and / or permeability in the subject.
[0031] The second embodiment of the present invention refers to the in vitro use of a five-carbon monosaccharide derived from the hydrolysis of a beta-galactoside substrate, or a kit comprising reagents for measuring the amount or concentration of the five-carbon monosaccharide derivedfrom the hydrolysis of a beta-galactoside substrate, for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject.
[0032] In a preferred embodiment the present invention comprises: a) administering an effective amount of a beta-galactoside substrate to the subject; b) measuring the amount or concentration of a five-carbon monosaccharide derived from the hydrolysis of the beta-galactoside substrate in a first biological sample at a baseline time point (Tl); c) measuring the amount or concentration of the same five-carbon monosaccharide derived from the hydrolysis of the betagalactoside substrate in a second biological sample at a follow-up time point (T2) after a defined period, and d) comparing the measurements obtained at Tl and T2 for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability; wherein the amount or concentration of the five-carbon monosaccharide directly correlates with the level of betagalactosidase enzyme activity in the intestine of the subject, and wherein the level of betagalactosidase enzyme activity is indicative of the degree of intestinal barrier integrity and / or permeability in the subject.
[0033] According to the present invention, and based on percentage calculations, a strong correlation between the increase in urinary xylose levels and the improvement of gastrointestinal symptoms was observed, as measured using a Visual Analogue Scale (VAS) from 0 to 10. Specifically, a 25% increase in urinary xylose (mg) corresponds to an average symptom improvement of 7 points on the VAS, while a 50% increase corresponds to an average improvement of 9 points. These findings support the use of urinary xylose for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject. So, in a preferred embodiment, a 25% increase of the five-carbon monosaccharide is indicative of a moderate improvement in intestinal barrier function (corresponding to an at least 7 points on a Visual Analogue Scale (VAS) for symptom severity); or a 50% increase of the five-carbon monosaccharide is indicative of a significant improvement in intestinal barrier function (corresponding to of at least 9 points on the VAS).
[0034] In a preferred embodiment, the beta-galactoside substrate is a substrate of lactase-phlorizin hydrolase, preferably a substrate that generates xylose upon hydrolysis by lactase-phlorizin hydrolase, most preferably selected from: 4-Galactosylxylose (4-O-B-galactopyranosyl D-xylose) (Gaxilose), 3-Galactosylxylose (3-O-B-galactopyranosyl D-xylose), 2-Galactosylxylose (2-O-B-galactopyranosyl D-xylose), lactose, 3-methyl-lactose, 14C-lactose, or 13C-lactose.In a preferred embodiment, the five-carbon monosaccharide is an aldopentose selected from D-ribose, D-arabinose, D-xylose, and D-lyxose; preferably, xylose.
[0035] In a preferred embodiment, the P-galactosidase enzyme is lactase.
[0036] In a preferred embodiment, the present invention refers to an in vitro method for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject, the method comprising: a) administering an effective amount of Gaxilose to the subject; and b) measuring the amount or concentration of xylose derived from the hydrolysis of Gaxilose in a biological sample obtained from the subject; wherein the amount or concentration of xylose correlates with the level of lactase enzyme activity in the intestine of the subject, and wherein the level of lactase enzyme activity is indicative of the degree of intestinal barrier integrity and / or permeability in the subject.
[0037] In a preferred embodiment, the method comprises assessing paracellular alterations, involving disruption of tight junctions between enterocytes, and / or transcellular alterations, affecting the transport mechanisms across enterocytes.
[0038] In a preferred embodiment, the beta-galactoside substrate (preferably Gaxilose) is administered orally.
[0039] In a preferred embodiment, the biological sample where the amount or concentration of a five-carbon monosaccharide derived from the hydrolysis of the beta-galactoside substrate is measured, is selected from urine, blood, plasma or serum.
[0040] In a preferred embodiment, the degree of intestinal barrier integrity and / or permeability is classified into categories selected from: low permeability / high integrity, moderate permeability / moderate integrity, and high permeability / low integrity.
[0041] So, the inventors have observed that changes in xylose amount or concentration between two time points provide a quantitative indication of changes in intestinal barrier integrity and / or permeability, and that such changes may be associated with varying degrees of clinical improvement. As indicated above, initial observations suggested that percentage increases of at least approximately 25% and 50% in xylose amount or concentration were among the changes observed in subjects exhibiting relevant improvements in gastrointestinal symptomatology. Subsequent data (see Example 2.8) obtained from an increased number of subjects have shown that higher percentage changes, including increases above 100%, may also be associated with clinically meaningful improvement, for example as reflected by valuesaround 8 on a symptom improvement scale, while more moderate increases have in some cases been associated with values around 6 on said scale. These findings illustrate that different magnitudes of change in xylose concentration may be indicative of improvement, and that no single percentage threshold or linear relationship is required to define a clinically relevant change, the interpretation being dependent on the subject, baseline condition and clinical context.
[0042] Further observations based on an increased number of subjects indicate that changes in xylose concentration between T1 and T2 may include both increases and decreases. When subjects are grouped according to the direction and magnitude of xylose change, the average values show that higher xylose increases are associated with lower average zonulin levels, whereas negative xylose changes are associated with higher average zonulin levels, consistent with the expected inverse trend between these parameters. These findings support interpreting the direction and magnitude of xylose change in a longitudinal manner for a given subject and indicate that both increases and decreases in xylose levels may provide clinically relevant information regarding changes in intestinal barrier integrity and / or permeability, particularly when considered in the context of baseline values and individual variability.
[0043] So, particularly, the present invention refers to an in vitro method for evaluating and / or monitoring the degree of integrity and / or permeability of the intestinal barrier of a subject. The method comprises determining, in vitro, the amount or concentration of xylose in a biological sample obtained from the subject at a first time point (Tl) and at a second time point (T2), wherein T2 is later than Tl. The amounts or concentrations of xylose determined at Tl and T2 are compared, and the variation of xylose between Tl and T2 is used as a quantitative indicator of a change in the degree of integrity and / or permeability of the intestinal barrier. In one embodiment, the invention also relates to the in vitro use of xylose determined in a biological sample obtained from a subject for evaluating and / or monitoring the degree of integrity and / or permeability of the intestinal barrier of the subject, wherein the xylose concentration or amount is determined at two different time points and the variation of xylose between said time points is used as the relevant parameter.
[0044] In one embodiment, the xylose determined in the biological sample originates from the intestinal hydrolysis of 4-galactosylxylose mediated by intestinal lactase. In this embodiment, 4-galactosylxylose is administered to the subject prior to obtaining the biological sample, and the xylose generated by enzymatic hydrolysis in the intestine is subsequently determined invitro in the biological sample obtained from the subject. The administration of 4-galactosylxylose forms part of the physiological context preceding the in vitro analysis, while all analytical and comparative steps of the method are carried out ex vivo.
[0045] In one embodiment, the biological sample obtained from the subject is a urine sample. The amount or concentration of xylose in the urine sample is determined using quantitative analytical techniques performed in vitro, including enzymatic assays, colorimetric assays, chromatographic methods, or combinations thereof.
[0046] In one embodiment, the evaluation of intestinal barrier integrity and / or permeability is based on the variation of xylose between T1 and T2, rather than on absolute xylose values measured at a single time point. The use of a relative percentage variation allows a more robust assessment of temporal changes and reduces the impact of inter-individual variability.
[0047] In one embodiment, the variation of xylose between T1 and T2 corresponds to an increase or a decrease in xylose amount or concentration.
[0048] In one embodiment, a percentage increase of xylose equal to or greater than 25% between T1 and T2 is indicative of a moderate improvement in intestinal barrier integrity and / or permeability.
[0049] In one embodiment, a percentage increase of xylose equal to or greater than 50% between T1 and T2 is indicative of a significant improvement in intestinal barrier integrity and / or permeability.
[0050] In one embodiment, a percentage increase of xylose equal to or greater than 100% between T1 and T2 is indicative of a clinically meaningful improvement in intestinal barrier integrity and / or permeability.
[0051] In one embodiment, a decrease in xylose concentration, defined as a percentage variation between T1 and T2 lower than 0%, is used as a quantitative indicator of worsening of intestinal barrier integrity and / or permeability when assessed longitudinally for a given subject.
[0052] In one embodiment, the method or in vitro use is performed in a longitudinal manner, wherein xylose concentrations are determined at two or more additional time points beyond T1 and T2, thereby allowing monitoring of changes in intestinal barrier integrity and / or permeability over an extended period of time.In one embodiment, the method or in vitro use is applied for monitoring intestinal barrier integrity and / or permeability in subjects undergoing dietary, nutritional, pharmacological or lifestyle interventions, wherein the variation of xylose over time reflect corresponding changes in the intestinal barrier.
[0053] In one embodiment, the invention further relates to an in vitro diagnostic kit comprising reagents for the quantitative determination of xylose in a biological sample and instructions for use for carrying out the in vitro method or in vitro use as described herein. The instructions may define one or more variation thresholds of xylose for classifying changes in intestinal barrier integrity and / or permeability, including thresholds indicative of moderate, significant or clinically meaningful improvement. For the purpose of the present invention the following terms are defined:
[0054] • As used herein, the term “in vitro" refers to measurements, determinations or analyses performed outside the human body on a biological sample previously obtained from a subject, without any therapeutic or surgical step being carried out on the subject during said determination.
[0055] • As used herein, the term “subject” refers to a human individual. The subject may be a healthy individual or an individual suffering from, suspected of suffering from, or being monitored for a condition associated with altered intestinal barrier integrity and / or permeability.
[0056] • As used herein, the term “biological sample” refers to any sample obtained from a subject that contains or is expected to contain xylose following administration of 4-galactosylxylose. Non-limiting examples of biological samples include urine, blood, plasma, serum or other bodily fluids, preferably urine.
[0057] • As used herein, the terms “evaluating” and “monitoring” refer to assessing the state of intestinal barrier integrity and / or permeability at a given time point and / or assessing changes therein over time, respectively. Monitoring may involve repeated measurements in the same subject to follow longitudinal variations.
[0058] • As used herein, the term “first time point (TI)” refers to an initial time at which a biological sample is obtained from the subject, and the term “second time point (T2)” refers to a later time at which a subsequent biological sample is obtained from the same subject, T2 being temporally subsequent to Tl.
[0059] • As used herein, the term “longitudinally” or “longitudinal assessment” means that measurements are performed at two or more time points in the same subject, allowingintra-subject comparison of changes over time rather than cross-sectional comparison between different subjects.
[0060] • As used herein, the term “xylose” refers to D-xylose detected or quantified in a biological sample of the subject, wherein said xylose originates from the intestinal hydrolysis of administered 4-galactosylxylose mediated by intestinal lactase.
[0061] • As used herein, the term “4-galactosylxylose” refers to a galactosylated xylose compound administered orally to the subject, which is hydrolyzed in the intestine by lactase to release xylose that can be absorbed and subsequently detected in a biological sample.
[0062] • As used herein, the term “percentage variation of xylose” refers to the relative change in the amount or concentration of xylose measured at the second time point (T2) compared to the first time point (Tl), expressed as a percentage. Said percentage variation may correspond to an increase or a decrease in xylose concentration between Tl and T2.
[0063] • As used herein, the term “percentage increase of xylose” refers to a positive percentage variation in xylose concentration between Tl and T2, wherein the amount or concentration of xylose at T2 is higher than that determined at Tl.
[0064] • As used herein, a “percentage variation of xylose equal to or less than 0%” refers to a situation in which the amount or concentration of xylose at T2 is equal to or lower than that measured at Tl, including cases of no change and cases of a decrease in xylose concentration.
[0065] • As used herein, the term “quantitative indicator” refers to a measurable numerical parameter derived from xylose determination that provides information about changes in intestinal barrier integrity and / or permeability. Such indicator may be expressed, for example, as a relative change between two time points, including a percentage increase and / or a ratio between the values obtained at T2 and Tl. A quantitative indicator does not require a fixed threshold or a linear relationship and may be interpreted in the context of longitudinal measurements for a given subject.
[0066] • As used herein, the terms “moderate improvement”, “significant improvement” and “clinically meaningful improvement” refer to different degrees of improvement in intestinal barrier integrity and / or permeability, as reflected by the magnitude of the percentage increase in xylose and / or associated clinical observations, without implying a strict or universal quantitative relationship.• As used herein, the term “diagnostic kit” refers to a collection of reagents and instructions for use suitable for carrying out the in vitro method or in vitro use described herein, including reagents for the quantitative determination of xylose in a biological sample and guidance for interpreting xylose variations.
[0067] • "Intestinal barrier integrity" refers to the functional condition of the intestinal barrier, which includes the epithelial cells lining the intestines, the tight junctions between these cells, and the mucosal layer. An intact intestinal barrier prevents the passage of harmful pathogens, toxins, and undigested food particles into the bloodstream, thereby maintaining immune homeostasis and preventing inflammation. Loss of integrity leads to increased permeability of the intestinal barrier, which is associated with various gastrointestinal diseases and systemic conditions.
[0068] • "Intestinal barrier permeability" refers to the ability of the intestinal barrier to allow the passage of substances, including nutrients, water, and small molecules, across the epithelial cell layer. Normal permeability is necessary for nutrient absorption, while increased permeability can be indicative of intestinal dysfunction, inflammation, or disease. Increased intestinal permeability is commonly referred to as "leaky gut," and it has been associated with various health conditions, such as inflammatory bowel disease (IBD), celiac disease, and autoimmune diseases.
[0069] • "Comprising" refers to an open-ended term indicating that the listed components or steps are included, but the method, composition, or system may also include other unlisted components or steps.
[0070] • "Consisting of is a closed-ended term indicating that the listed components or steps are the only ones included, and no additional components or steps are allowed beyond those specified.
[0071] Description of the figures
[0072] Figure 1. Evolution of xylose and zonulin levels in the 13 patients that increased xylose levels between the two different time points. A) Changes in xylose levels. Patients showing an increase in xylose levels at time point 2. B) Changes in zonulin levels. The same patients showing a decrease or increase in zonulin levels at time point 2. The red line indicates cutoff values. Patients who changed their diagnosis from hypolactasic to normolactasic are identified with two asterisks. Patients whose zonulin levels decreased at Time Point 2 are identified with an asterisk.Detailed description of the invention
[0073] The present invention is illustrated by means of the Examples set below without the intention of limiting its scope of protection.
[0074] Example 1. MATERIAL AND METHODS
[0075] Example 1.1. Pilot study overview with patients with gastrointestinal symptoms With the aim of evaluating the possible association between lactase enzyme activity and changes in the intestinal barrier integrity that affect intestinal permeability, we developed a pilot study to investigate this relationship. The study focused on patients with functional digestive disorders, characterized by dysbiosis, with a significant proportion also presenting small intestinal bacterial overgrowth.
[0076] Example 1.1.2. Study design and patient cohort
[0077] The study cohort consisted of 25 patients with a mean age of 44 years (ranging from 23 to 77 years). The cohort included 5 men and 20 women. These participants were selected due to their functional digestive disorders and the presence of intestinal microbial imbalances, which have been implicated in altering intestinal permeability.
[0078] Example 1.1.3. Testing and methodology
[0079] All participants underwent zonulin and Gaxilose tests at two different intervals, in stool and urine respectively, with a mean duration between tests of 425 days (ranging from 271 to 651 days). Zonulin, a known biomarker of intestinal permeability, was measured as an indication of changes in the tight junctions of the intestinal epithelial cells. The Gaxilose test was used to measure xylose levels in biological samples to assess lactase enzyme activity and to further explore the potential connection between lactase activity and intestinal barrier integrity and permeability.
[0080] Example 1.1.4. Intervention and follow-up
[0081] After the first round of testing, the patients followed a dietary regimen, and a treatment protocol aimed at addressing dysbiosis and promoting intestinal health. This regimen was designed to influence intestinal microbiota composition and potentially improve intestinal permeability. The second round of tests was performed after the patients had adhered to the diet and treatment plan, allowing for the evaluation of changes in intestinal permeability and lactase activity.Example 1.1.5. Study goals and expected outcomes
[0082] The primary objective of this pilot study was to investigate the potential relationship between lactase enzyme activity (as measured through xylose levels) and intestinal barrier integrity (addressed with zonulin levels) in the context of functional digestive disorders. By assessing zonulin and xylose in patients before and after dietary and therapeutic intervention, we aimed to better understand how changes in intestinal permeability correlate with lactase activity and the effects of treatments designed to restore microbial balance.
[0083] According to our study, and based on percentage calculations, we observed a strong correlation between the increase in urinary xylose levels measured in urine and the improvement of gastrointestinal symptoms, as measured using a Visual Analogue Scale (VAS) from 0 to 10. Specifically, a 25% increase in urinary xylose (mg) corresponds to an average symptom improvement of 7 points on the VAS, while a 50% increase corresponds to an average improvement of 9 points. These findings support the use of urinary xylose for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject.
[0084] Example 1.2. Tests preparation
[0085] Example 1.2.1. The Gaxilose test
[0086] The Gaxilose test requires the following preparation steps:
[0087] • Fasting: The patient must fast for at least 10 hours prior to the test.
[0088] • Initial urine collection: Once the 10-hour fasting period has passed, the patient should empty their bladder for the last time. This initial urine should not be collected.
[0089] • Gaxilose ingestion: The patient should then dissolve the contents of a 0.45g Gaxilose sachet in half a glass of water and drink the entire solution.
[0090] • Urine collection: Following the ingestion of Gaxilose, the patient must collect all urine over the next 5 hours. The patient must not consume any food during the test. They may drink a maximum of 500 ml of water (approximately two glasses) within the first two hours of the test.
[0091] • Final urine collection: At the end of the 5-hour period, the patient should empty their bladder again and collect the final urine sample to complete the test.
[0092] • Urine volume and storage: The total urine volume should be recorded, and the urine should be stored in the refrigerator at home until the visit to the consultation, usually 24h after the collection. The urine will be used for xylose measurement.Example 1.2.2. Xylose measurement
[0093] The xylose concentration in the collected urine will be measured using the 0saxyl7000 Point of Care device. This method has been approved by the Spanish Agency of Medicines and Medical Devices. A cut-off point of >19.18 mg of xylose per urine sample is indicative of normolactasia. If the measured value is below this threshold, the patient may be classified as hypolactasic. Apart from classifying the patients as hypo or normolactasic, changes in xylose after Gaxilose ingestion give us a value of intestinal barrier integrity and intestinal permeability.
[0094] Example 1.2.3. Zonulin test
[0095] For the zonulin test:
[0096] • Stool Sample Collection: Patients are required to collect a stool sample using the container provided in the Zonulin Kit from the Institute of Microecology. The sample should be from a single bowel movement. Do not mix stool from different bowel movements.
[0097] • Sample Delivery: The stool sample should be delivered to the consultation on the same day or a different day as the urine sample, as specified in the prior telephone instructions.
[0098] • No Fasting Required: No fasting is required for this test, but it can be done at the same time as the Gaxilose test.
[0099] Example 1.2.4. Zonulin cut-off
[0100] In this study, the cut-off point for zonulin levels is 78-100 ng / mL. If the measured level is below 78 ng / mL, zonulin levels are considered normal.
[0101] Example 1.3 Validation of Gaxilose for use in the assessment of intestinal barrier integrity in an in vitro model
[0102] In this work we aim to show that, in an in vivo model of intestinal barrier integrity, Gaxilose is not absorbed and can be used in the assessment of intestinal barrier integrity.
[0103] Methotrexate (MTX) has been used to induce mucositis, a severe side effect of chemotherapy, that may cause reduction or interruption of cancer treatment in in vivo models. MTX induced significant and dose-dependent villous atrophy and elongation of crypts in duodenumjejunum,and ileum. MTX caused major changes in small bowel function by disrupting intestinal permeability and inducing electrolyte secretion in parallel with substantial histological damage.
[0104] The objective of the present study is to compare the intestinal absorption of the test item Gaxilose (GXL) with the reference item Lactulose / Mannitol mixture (L / M) in an MTX-induced intestinal barrier injury induced by the administration of MTX in male Sprague Dawley rats.
[0105] Methodology
[0106] For this purpose, a total of 80 Sprague Dawley rats were distributed into 5 experimental groups (A, B, C, D and E), consisting of 16 males each. Each experimental group was further divided into 4 different allocations, namely D4, D6, D8 and Dll, corresponding to different treatment / sacrifice rounds that took place on day of study 4, 6, 8 and 11 respectively according to Table 1:
[0107] Table 1
[0108] Group Intestinal damage Test Item Treatment / Sacrifice round (MTX / vehicle)
[0109] (on days 1,2 and 3) Day 4 Day 6 Day 8 Day 11
[0110] Animal ID
[0111] A No / saline water 1-4 21-24 41-44 61-64 B No / saline L / M 5-8 25-28 45-48 65-68 C Yes / MTX (2.5 mg / kg) L / M 9-12 29-32 49-52 69-72 D No / saline GXL 13-16 33-36 53-56 73-76 E Yes / MTX (2.5 mg / kg) GXL 17-20 37-40 57-60 77-80
[0112]
[0113] MTX= methotrexate, L / M = lactulose / manitol, GXL=gaxilose. Each allocation contained a total of 4 animals per group.
[0114] Male rats in groups C and E were subjected to intestinal barrier injury by subcutaneous administration of 2.5 mg / kg MTX during 3 consecutive days: days 1, 2 and 3 of the study. Animals in groups A, B and D received equal volumes of saline subcutaneously on days 1,2 and 3. The dose volume was adjusted according to the body weight on the days of administration.Body weight was measured daily. Animals were checked regularly for any clinical signs, discomfort and mortality according to the OCDE Humane Endpoints Guidance Document. Depending on their allocation, animals in the different groups were treated by oral gavage with a single dose of 25 mg / animal Gaxilose, or 25 mg / animal lactulose and 25 mg / animal mannitol on study days 4, 6, 8 and 11, respectively. All animals were fasting for approximately 10 hours before treatment. Milli Q water was used as control.
[0115] Six hours after the Gaxilose, lactulose / mannitol or vehicle treatment, cumulative urine was collected, and animals were sacrificed on the respective days and subjected to gross necropsy. Urine was collected after drug administration, and during the first 6 hours after administration. The total volume of the 6-hours accumulated urine was measured, and samples were frozen and stored until processing.
[0116] Histopathology
[0117] At completion of the 6h urine-collection period, animals were sacrificed by CO2 overdose. Immediately thereafter, a gross necropsy was performed. Two animals from groups A, C and E were randomly selected for histopathology analysis using a true random number generator application from www. Random.org. If jejunum samples from the mentioned animals could not be obtained, the tissue from the next animal was chosen. Samples of the jejunum and tissues showing gross abnormalities were collected and fixed in 4% neutral buffered formaldehyde. The jejunum was processed into hematoxylin and eosin-stained slides from those animals for microscopic evaluation. A minimum of four sections per animal were cut at a nominal thickness of 4-5 pm. Histopathological evaluation was performed by the delegated phase (Insight Pathology) in the selected samples A minimum of 4 slices of jejunum medium were made available for histopathological analysis.
[0118] Samples of the following animal numbers were prepared for microscopic evaluation (Table 2):Table 2
[0119] Group Intestinal damage Test Item Histopathologic evaluation (MTX / vehicle)
[0120] (on days 1,2 and 3) Day 4 Day 6 Day 8 Day 11
[0121] Animal ID
[0122] A No / saline Milli Q water 2, 3 23, 24 42, 44 61, 64 C Yes / MTX (2.5 mg / kg) L / M 11,12 30, 32 49, 52 69, 70 E Yes / MTX (2.5 mg / kg) GXL 18, 20 37, 40 58, 59 79, 80
[0123]
[0124] Slides were examined by light microscopy.
[0125] During microscopy, the depth of the crypts and the height of the villi were measured on a single cross-section selected based on the highest histological quality. For these measurements, a digital image was taken from the mucosa of the jejunum of each animal at one single magnification (using a 5x lens) using Zen software (Zeiss). Prior to these measurements, the system was calibrated with a micrometer (using a micrometer of 200x0.01=2mm from Pyser-SGI Ltd., UK). The height of the villi and the depth of the crypts were measured in pm. The mean of the five measurements was calculated. The total mucosal height was calculated from those results as the sum of both crypt depth and villous height and the villous / crypt ratio was additionally calculated.
[0126] Determination of different sugars in urine and serum samples of adult rats by gas chromatography
[0127] Then, different sugars were determined in urine and serum samples of adult rats by gas chromatography. 50 pl of urine or serum was lyophilized. The residue was resuspended in 20 pL of internal standard (sucrose in pyridine, 0.4 mg / mL) and 20 pL of N-trimethylsilyl-imidazole. The mixture was heated at 60 °C for 30 min and analyzed in the gas chromatograph. Measurements of Gaxilose, lactulose and mannitol in urine and serum samples were performed in a gas chromatograph (Hewlett Packard 5890), using a column (DB-1701, 30 m x 0.32 mm x 0.25 pm). The program temperature was as follows: initial temperature: 170°C (9 min), followby 20°C / min and 210°C (40 min). We injected 3 pL of sample. The injector temperature was 220°C; the detector temperature was 260°C; ratio: 80: 1 and the analysis time 50 minutes. Analyses were carried out using an Agilent 7890A Gas Chromatograph coupled to an Agilent 5975C Mass Spectrometry Detector.
[0128] Histopathology of the jejunum
[0129] Day 4 sacrifices
[0130] The jejunum of methotrexate-treated animals showed a variety of changes regardless treatment with L / M or Gaxilose, compared to the control animals. These changes consist of atrophy of epithelial cells (mainly within the crypts), loss of crypt-lining (progenitor) cells by increased apoptosis also leading to crypts filled with debris and reduced mitotic activity (visible as a marked decreased number of mitotic figures) in the crypts. Paneth cells however were still observed, suggesting that this cell type was relatively less affected by methotrexate. Goblet cells within the villi were, as the Paneth cells, fairly spared by the action of methotrexate Day 6 sacrifices
[0131] Six days after the methotrexate treatment, only some remnants of the effects observed after 4 days remained. There was still a minor increase in apoptotic bodies and there were some crypts with minor debris. At the top of the villi, the epithelial cells showed vacuolar degeneration. On the opposite, an increased proliferative activity (increased number mitotic figures) was observed within the crypts. The crypts became taller and slightly wider compared to control animals, while few animals concomitantly showed slight villous atrophy as resultant of the earlier reduced mitotic activity. This hyperplasia of the progenitor cells within the crypts suggests that the animals recovered from the mucosal cell loss in the first days after methotrexate treatment by increasing the cell-turnover.
[0132] Day 8 sacrifices
[0133] Two days after the events, as described for the day 6 sacrifices, the increase in cell turnover seems to have disappeared. However, the result of this wave of proliferation was still evidenced by slight mucosal hypertrophy.
[0134] Day 11 sacrifices
[0135] Eleven days after the methotrexate treatment the morphology of the mucosa of the jejunum returned to normal.Example 2. RESULTS
[0136] Example 2.1. Patients with an increase in xylose levels at time point 2 with respect time point 1
[0137] Table 3 focus on patients with an increase in xylose levels at time point 2:
[0138] Table 3
[0139] Patients Xylose changes (mg) Zonulin changes (ng / mL) Symptoms improvement scale 0-10 time point 1 / time point 2 time point 1 / time point 2
[0140] 3 24.4 / 30.6 17.28 / 37.63 7
[0141] 4 24.2 / 29.8 129.14 / 10 9
[0142] 6 24.4 / 35.4 111.25 / 29.2 8
[0143] 7 14.9 / 50.8 28.86 / 5.99 8.5
[0144] 9 12.3 / 20.3 41.02 / 28.43 7
[0145] 10 22.4 / 49.4 119.81 / 59.18 9
[0146] 11 25.9 / 51.7 39.05 / 17.08 9
[0147] 14 11.6 / 20.1 168.24 / 12.24 6.5
[0148] 15 5.7 / 18.4 75 / 10 9
[0149] 16 24 / 36 10 / 54.37 7
[0150] 18 14.5 / 21 14.85 / 44.44 - 20 4.8 / 58.9 140.12 / 47.94 - 24 27.1 / 41.1 128.6 / 95.58 5
[0151]
[0152] At time point 2, 13 patients showed an increase in xylose levels, indicating an improvement in intestinal barrier integrity. Among these 13 patients, 10 also showed a decrease in zonulin levels (marked in bold in Table 3), further suggesting enhanced intestinal barrier integrity (see Table 3 and Figure 1).
[0153] Example 2.2. Patient response to test results
[0154] Five patients (patients 7, 9, 14, 18, 20) transitioned from a diagnosis of hypolactasia to normolactasia according to the cut off limit of 19.18mg established with this methodology, indicating an improvement in lactase activity as measured by xylose levels.
[0155] Five patients (patients 4, 6, 10, 14, 20) transitioned from being zonulin-positive (indicating increased intestinal permeability) to zonulin-negative (indicating normal zonulin levels), suggesting an improvement in intestinal barrier integrity.Example 2.3. Gastrointestinal symptom improvement
[0156] Feedback from the patients regarding their gastrointestinal symptoms was obtained using a 10-point scale, which was administered after medical advice, treatment and dietary adjustments following the first test. Of the 13 patients who showed an improvement in xylose levels:
[0157] • 11 patients reported symptom relief on the 10-point scale.
[0158] • Two patients did not report significant improvement:
[0159] o Patient 18 was lost to follow-up due to interruption of clinic visits. o Patient 20 did not notice any symptom improvement, which may be attributed to challenges in complying with the prescribed dietary restrictions.
[0160] Example 2.4. Observations from patients with low xylose levels
[0161] Table 4 focus on patients with low levels of xylose in both time points.
[0162] Table 4
[0163] Patients Xylose changes (mg) Zonulin changes (ng / mL) Symptoms improvement scale 0-10 time point 1 / time point 2 time point 1 / time point 2
[0164] 1 7.5 / 7.5 133.68 / 10 Slow progress
[0165] 12 3.9 / 4.7 146.42 / 39.69 Improvement and subsequent relapse 21 1.5 / 2.7 98.41 / 52.21 - 25 9.8 / 2.9 106.32 / 55.61 9
[0166]
[0167] In Table 4, we present data for four patients who had very low xylose levels at time point 1 and continued to show low levels at time point 2.
[0168] • Patients 1 and 12 showed slow evolution with only a minimal change in xylose levels.
[0169] Despite a decrease in zonulin, their symptoms improved slowly, possibly due to the longer time needed for the intestinal barrier to recover.
[0170] • Patient 21 was lost to follow-up after stopping clinical visits. This patient showed no significant change in xylose or zonulin levels at Time Point 2, and further monitoring was not possible.
[0171] • Patient 25, who remained asymptomatic at Time Point 2, exhibited a slight increase in xylose levels but showed a decrease in zonulin. which led us to suspect primary hypolactasia as a potential cause. This assumption could be confirmed through a genetic study.The results also suggest that, although symptoms may rapidly improve with the right treatment and diet, restoring the health of the intestinal barrier could require a longer period, which varies according to the individual pathology.
[0172] Example 2.5. Intestinal lactase activity and xylose for assessing and / or monitoring intestinal barrier integrity and / or permeability in a subject
[0173] Intestinal lactase activity is one of the first functions to be impaired during intestinal barrier alteration. Lactase, the enzyme responsible for hydrolyzing lactose, plays the role in the hydrolysis of Gaxilose, a disaccharide composed of galactose and xylose. Upon ingestion of Gaxilose, intestinal lactase cleaves it into xylose and galactose. The amount of xylose present and concentration in the urine and blood, respectively, correlates directly with the intestinal lactase activity, providing a measure of intestinal barrier integrity.
[0174] In patients with functional digestive disorders, the administration of Gaxilose and the measurement of zonulin levels were carried out at two different time points. These tests revealed that the levels of xylose in urine, along with changes in zonulin, underscore the potential of xylose for assessing and / or monitoring the degree of intestinal barrier integrity and / or permeability in a subject. The results suggest xylose as an indication for intestinal barrier integrity recovery in patients suffering from functional digestive diseases.
[0175] The findings from these tests indicate that xylose could be a promising tool for monitoring the restoration of intestinal health, potentially aiding in the diagnosis and management of functional gastrointestinal disorders.
[0176] Example 2.6. Statistical Analysis
[0177] A statistical analysis was conducted to evaluate changes in zonulin and xylose levels at two different time points. The mean pre-post differences were calculated along with their 95% confidence intervals (CI) and paired-sample t-tests were applied. Correlations were assessed using Pearson or Spearman coefficients, depending on data normality, accompanied by their respective hypothesis tests.
[0178] The analysis revealed a significant decrease in zonulin levels at time point 2 (Mean change: -36.01 ng / mL; 95% CI: [-61.2, -10.83]; p = 0.007) and a significant increase in urinary xylose levels (Mean change: +6.99 mg; 95% CI: [0.22, 13.8]; p = 0.044). These results suggest that the therapeutic intervention effectively enhances intestinal barrier function, as indicated by decreased zonulin and increased xylose levels.A significant negative correlation was observed between changes in zonulin and xylose at time point 1 (Pearson's r = -0.49; p = 0.016), indicating that higher xylose levels are associated with lower zonulin levels. However, no significant correlation was found between zonulin and xylose levels at time point 2 (Pearson's r = -0.15; p = 0.470), nor between their absolute or relative changes over time (Pearson's r = -0.17; p = 0.414), suggesting that the therapeutic intervention may differentially affect these biomarkers.
[0179] Regarding symptom improvement, no significant correlation was found between changes in zonulin levels and symptom scores (Spearman's p = 0.03; p = 0.887). In contrast, a significant positive correlation was observed between changes in xylose levels and symptom improvement (Pearson's r = 0.60; p = 0.002), supporting the use of urinary xylose as a reliable marker for assessing both intestinal barrier integrity and clinical response.
[0180] Based on this study, it's possible to propose a stratification of intestinal barrier integrity or permeability levels using xylose measurements. The data indicates that increases in urinary xylose levels correlate with symptom improvement, suggesting that xylose can serve as a surrogate marker for intestinal barrier function.
[0181] For instance, a 25% increase in urinary xylose corresponds to an average improvement of 7 points on the Visual Analogue Scale (VAS), while a 50% increase corresponds to an average improvement of 9 points. These correlations support the use of urinary xylose levels to assess and monitor the degree of intestinal barrier integrity and / or permeability in a subject.
[0182] Example 2.7. Validation of Gaxilose for use in the assessment of intestinal barrier integrity
[0183] Comparison of group B (saline plus L / M) and group C (MTX plus L / M), 4 rats per group On day 4 an abnormal (lactulose / mannitol ratio) LMR was due to higher excretion of lactulose in the urine rather than a reduced excretion of mannitol, supporting the data that there is an increase in intestinal permeability on day 4 that increase the permeation of lactulose. Conclusion: On day 4 which is the day with more intestinal barrier damage, there is a higher ratio of L / M in urine, which means that there is more lactulose passing through.Table 5
[0184] LMR 4 0.342 (0.103) 0.521 (0.099) 0.025
[0185]
[0186] Comparison of group D (saline plus GXL) and group E (MTX plus GXL), 4 rats per group Table 6
[0187] Parameter Day Control group, Treated group, mean p value
[0188] mean (SD) (SD)
[0189] GXL 4 0.391 (0.306) 0289 (0.196) 0.611
[0190] excretion (%) 6 0.812 (0.339) 0.365 (0.252) 0.079
[0191] 8 0.743 (0.329) 0.538 (0.149) 0.3
[0192] 11 0.341 (0.251) 0.672 (0.257) 0.115
[0193]
[0194] In conclusion, there are no differences in Gaxilose v the control at any time point, which means that Gaxilose is not absorbed by the intestinal barrier.
[0195] Example 2.8. Validation in an expanded cohort (n=55): association of longitudinal xylose changes with symptom improvement and zonulin values
[0196] An expanded-cohort analysis was performed to examine whether longitudinal changes in xylose concentration between two time points (T1 and T2), following administration of 4-galactosylxylose, provide a quantitative indication of changes relevant to intestinal barrier integrity and / or permeability, and to describe their association with gastrointestinal symptom improvement and zonulin trends.
[0197] An expanded dataset comprising N = 55 subjects was analyzed. For each subject, xylose levels were measured at an initial time point (Tl) and at a later time point (T2). The percentage variation in xylose concentration between Tl and T2 was calculated. Clinical improvement was assessed using a 0-10 symptom improvement scale, where 0 indicates no improvement and 10 indicates maximal improvement.
[0198] Grouping based on longitudinal xylose changes
[0199] Subjects were grouped based on the direction and magnitude of the percentage change in xylose concentration between Tl and T2 using two grouping approaches:(1) Grouping by magnitude relative to 100% (symptom improvement analysis):
[0200] Group A: >100% increase in xylose concentration.
[0201] Group B: 0-100% increase in xylose concentration.
[0202] Group C: decrease in xylose concentration.
[0203] (2) Grouping incorporating zonulin values:
[0204] Strict claim-based grouping:
[0205] >50% increase in xylose; >25% increase in xylose (including >50%); and <0% change in xylose, corresponding to subjects who worsen and show a decrease in xylose concentration. Range grouping:
[0206] >50% increase in xylose; 25-50% increase in xylose; and <0% change in xylose, corresponding to subjects who worsen and show a decrease in xylose concentration.
[0207] For the groups incorporating zonulin, mean percentage changes in xylose concentration and mean zonulin percentage values were compared across groups to assess trends.
[0208] (A) Symptom improvement according to xylose change magnitude
[0209] Mean symptom improvement scores (0-10 scale) were as follows:
[0210] >100% increase in xylose: mean symptom improvement score of 8.
[0211] 0-100% increase in xylose: mean symptom improvement score of 6.
[0212] Decrease in xylose: mean symptom improvement score of 6.
[0213] These results indicate that symptom improvement was observed across all groups, including in subjects exhibiting decreases in xylose concentration between T1 and T2, with the highest mean improvement observed in subjects showing increases in xylose greater than 100%. (B) Mean xylose and zonulin values across groups
[0214] When mean values were compared across groups, an inverse trend between xylose and zonulin was observed.
[0215] Strict claim-based grouping (>50%; >25% including >50%; <0%):
[0216] Mean xylose values: -37% < 163% < 233%.Mean zonulin values: 246% > 116% > 75%.
[0217] Range grouping (>50%; 25-50%; <0%):
[0218] Mean xylose values: -37% < 38% < 233%.
[0219] Mean zonulin values: 246% > 188% > 75%.
[0220] In both grouping approaches, higher average increases in xylose concentration were associated with lower average zonulin values, whereas negative or non-positive changes in xylose concentration were associated with higher average zonulin values.
[0221] In conclusion, this expanded-cohort analysis (N = 55) shows that longitudinal changes in xylose concentration between T1 and T2 provide a quantitative indication of changes relevant to intestinal barrier integrity and / or permeability. Subjects exhibiting increases in xylose concentration greater than 100% showed a mean symptom improvement score of 8, while subjects with smaller increases or with decreases in xylose concentration showed mean scores of 6. In addition, group-based comparisons demonstrated an inverse trend between xylose concentration changes and zonulin values, with increasing xylose associated with decreasing zonulin on average, and subjects with <0% changes, corresponding to those who worsen and show a decrease in xylose concentration, showing higher zonulin values.
Claims
TlCLAIMS1. An in vitro method for evaluating and / or monitoring the degree of integrity and / or permeability of the intestinal barrier of a subject, the method comprising:(a) determining in vitro the amount or concentration of xylose in a biological sample obtained from the subject at a first time point (T 1 );(b) determining in vitro the amount or concentration of xylose in a biological sample obtained from the subject at a second time point (T2), T2 being later than Tl; and(c) comparing the amounts or concentrations of xylose determined at Tl and T2, wherein the xylose is present in the biological sample following administration of 4-galactosylxylose to the subject prior to obtaining the biological sample, and wherein the variation of xylose between Tl and T2 is used as a quantitative indicator of a change in the degree of integrity and / or permeability of the intestinal barrier.
2. In vitro use of xylose determined in a biological sample obtained from a subject for evaluating and / or monitoring the degree of integrity and / or permeability of the intestinal barrier of the subject, wherein the amount or concentration of xylose is determined at a first time point (Tl) and at a second time point (T2), and the variation of xylose between Tl and T2 is used as a quantitative indicator of a change in the degree of integrity and / or permeability of the intestinal barrier.
3. The in vitro method or use, according to any of the claims 1 or 2, wherein the xylose determined originates from the intestinal hydrolysis of 4-galactosylxylose mediated by intestinal lactase.
4. The in vitro method or use, according to any of the previous claims, wherein the biological sample is a urine sample; or a blood, serum or plasma sample.
5. The in vitro method or use, according to any of the previous claims, wherein the variation of xylose between Tl and T2 may be an increase or a decrease.
6. The in vitro method or use, according to any of the previous claims, wherein a percentage increase of xylose equal to or greater than 25% between Tl and T2 is indicative of a moderate improvement in intestinal barrier integrity and / or permeability.
7. The in vitro method or use, according to any of the previous claims, wherein a percentage increase of xylose equal to or greater than 50% between Tl and T2 isindicative of a significant improvement in intestinal barrier integrity and / or permeability.
8. The in vitro method or use, according to any of the previous claims, wherein a percentage increase of xylose equal to or greater than 100% between T1 and T2 is indicative of a clinically meaningful improvement in intestinal barrier integrity and / or permeability.
9. The in vitro method or use, according to any of the previous claims, wherein a decrease in xylose amount or concentration, defined as a variation between T1 and T2 lower than 0%, is used as a quantitative indicator of worsening of intestinal barrier integrity and / or permeability when assessed longitudinally for a given subject.
10. The in vitro method or use, according to any of the previous claims, wherein the evaluation or monitoring is performed longitudinally by determining xylose at two or more additional time intervals.
11. An in vitro diagnostic kit comprising:(i) reagents for the quantitative determination of xylose in a biological sample;and(ii) instructions for use for carrying out the in vitro method or in vitro use according to any one of claims 1 to 10.
12. The kit, according to claim 11, wherein the instructions define one or more variation thresholds of xylose for classifying changes in intestinal barrier integrity and / or permeability.
